A A2-E 21 ABCA4 gene 37 Acquired hyperopia 67
Acute idiopathic blind spot enlargement syndrome (AIBSES) 58
Acute macular neuroretinopathy (AMN) 58 Acute zonal occult outer retinopathy
(AZOOR) 58 ff.
Adult vitelliform macular dystrophy 27 Adult-onset vitelliform macular dystrophy 43 Age-Related Eye Disease Study
(ARED study) 112
Age-related macular degeneration see macular degeneration
AIBSES see acute idiopathic blind spot enlargement syndrome
AMN see acute macular neuroretinopathy Anecortave acetate 171
Angiogenesis 101, 102 Antioxidant 112 APO*E3 98
ARED study see Age-Related Eye Disease study Aspirin 174
Autosomal dominant cystoid macular oedema see macular oedema
Autosomal dominant drusen see drusen AZOOR see acute zonal occult outer retinopathy B
Benign concentric annular macular dystrophy 45
Best disease 27
Best vitelliform macular dystrophy (s. also Best disease) 35, 39
Branch retinal vein occlusion (BRVO) 9, 146 Bruch’s membrane 99, 104
BRVO see branch retinal vein occlusion Bull’s eye macular dystrophy 45 Bullous detachment of the retina 83 Butterfly-shaped macular dystrophy 48
Cb-Carotene 167
Central areolar choroidal dystrophy 46 Central retinal vein occlusion (CRVO) 146 Central serous chorioretinopathy (CSC) 77, 82,
147
Choroidal folds 65 Choroidal neoplasm 70
Choroidal neovascularization (CNV) 11, 70, 95 – predominantly classic 129
– occult 11 – well-defined 11
Chronic CSC see central serous chorioretinopathy Chronic pre-phthisical ocular hypotony 152 Cigarette smoking 96
CNV see choroidal neovascularization COD1 43
Confocal scanning laser ophthalmoscopy 21 C-reactive protein 96
CRVO see central retinal vein occlusion Cyclooxygenase inhibitor 175
Cystoid macular oedema see macular oedema D
Diabetic macular oedema see macular oedema Diabetic retinopathy 6, 144
Diffuse retina pigment epitheliopathy 82 Dorzolamide 174
Doyne honeycomb dystrophy 47 Drusen 25, 113, 166
– autosomal dominant 47 E
EFEMP1 gene 48
Epiretinal membrane 13, 15 Etaretin 175
Eye Disease Case Control Study 96 F
FAM study 22 Fibronectin 99
Subject Index
11_Holz_Subject 09.02.2005 11:59 Uhr Seite 183
Fibrovascular pigment epithelium detachment 11
Fluorescein angiography 8 Foveal telangiectasias 147
Fundus autofluorescence imaging 19ff.
Fundus flavimaculatus 27 Fundus pulverulentus 48 G
GCAP1 43 Genistein 175
Geographic atrophy 22, 29, 115 H
High-resolution in vivo fundus autofluorescence imaging 31
Hypertension 96 Hypotony 69 I
Idiopathic choroidal folds 69
Indocyanine green (ICG) angiography 80 Interference 2
Interferometry 2 Interferon- α2a 173 Intracranial pressure 69 Ischaemia 101, 103 K
Kjellin’s syndrome 28 L
Laminin 99 Lesion size 133 Lipofuscin 20, 97, 107 Lipofuscinogenesis 20 Low-dose chemotherapy 172 Lucentis 169
Lutein 29, 168 M
Macugen 169
Macular degeneration, age-related 1, 11, 22, 144, 148
Macular dystrophy 35 Macular hole 9 Macular oedema 1, 5, 12 – cystoid 7
– – autosomal dominant 44 – diabetic 6, 144
– postoperative 15
– pseudophakic cystoid 146 Macular pigment density 29 Malattia Leventinese 47
Matrix metalloproteinase inhibitor 171 Matrix metalloproteinases 102
MCP see multifocal choroiditis and panuveitis Mean foveal thickness 5
Methotrexate 172
MEWDS see multiple evanescent white dot syndrome
Microperimetry 27 Müller cells 7
Multifocal choroiditis and panuveitis (MCP) 58, 138
Multifocal pattern dystrophy 48 Multiple evanescent white dot syndrome
(MEWDS) 58 N
Neovascular glaucoma 147 Neovascular iris vessel 147
North Carolina macular dystrophy 50, 51 N-retinylidene-N-retinylethanolamine (A2-E) 98 O
OCT see optical coherence tomography Ocular histoplasmosis 138
Ocular hypertension 153 Optic nerve pits 86 Optic neuropathay 73
Optical coherence tomography (OCT) 1, 3, 88 – resolution 3
Orbital masses 72 Oxidative damage 110, 165 Oxidative stress 106 P
Pars plana vitrectomy 145 Pathologic myopia 137 Pattern dystrophy 48
PCV see polypoidal choroidal vasculopathy PDT 12
PEDF see pigment epithelium-derived factor Pegabtanib 169
Penetrating keratoplasty 147 Peripherin/RDS gene 44, 46, 49 Photocoagulation therapy 89 Photodynamic therapy 90, 129 Photopsia 58
Pigment epithelial detachment 26
Pigment epithelium-derived factor (PEDF) 100, 109, 169, 171
Polypoidal choroidal vasculopathy (PCV) 138 Polyunsaturated fatty acid (PUFA) 108 Posterior hyaloid traction 8
Posterior scleritis 71
Postinjection infectious endophthalmitis 155 184 Subject Index
11_Holz_Subject 09.02.2005 11:59 Uhr Seite 184
Postinjection pseudoendophthalmitis 155 Postinjection sterile endophthalmitis 155 Prinonmastat 171
Progressive bifocal chorioretinal atrophy 49 Progressive cone dystrophy 41
Proliferative vitreoretinopathy 144, 151 Pseudophakic cystoid macular oedema
see macular oedema
PUFA see polyunsaturated fatty acid R
Radial drusen 47 Ranibizumab 169 Reticular dystrophy 48 Retinal folds 66 Retinitis pigmentosa 13
Rhegmatogenous retinal detachment 156 S
Scleral buckle 72
Sorsby fundus dystrophy 50 Staphylomal 73
Stargardt disease 27, 35, 36 Steroid induced cataract 156 Subretinal deposit 84 T
TAP study 130, 137 TIMP-3 gene 48
Triamcinolone 143, 153, 172
U
Ultrasonography 66 Ultrasound 1 Uveitis 10, 153 V
Vascular endothelial growth factor (VEGF) 102, 109, 169
VEGF see vascular endothelial growth factor Verteporfin Therapy with Altered Light
in Occult CNV (VALIO) study 135 VIM study 131
VIP study 132, 133 Visual acuity 10 Vitamin A 166 Vitamin C 167 Vitamin E 166, 167
Vitreomacular traction syndrome 1 Vitreoretinal interface 13
VKH see Vogt-Koyanagi-Harada syndrome VMD2 gene 41, 44, 45
Vogt-Koyanagi-Harada syndrome (VKH) 72 X
X-linked juvenile retinoschisis 35, 38 Z
Zeaxanthin 29, 168 Zinc 166
Subject Index 185 11_Holz_Subject 09.02.2005 11:59 Uhr Seite 185
